{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:22:06Z","timestamp":1789590126311,"version":"build-2803163510"},"reference-count":13,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,11,2]]},"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:p>A 48-year-old man with a history of schizophrenia was diagnosed with B-cell lymphoma of the small bowel. Neutropaenia occurred secondary to chemotherapy, which led to clozapine being discontinued, which resulted in the deterioration of his mental state, in turn, affecting the treatment of lymphoma. Clozapine was later reintroduced alongside granulocyte colony-stimulating factor, leading to improved mental state without any further incidences of neutropaenia.<\/jats:p>","DOI":"10.1136\/bcr-2020-238377","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T23:30:59Z","timestamp":1607902259000},"page":"e238377","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Clozapine and chemotherapy: a dangerous couple or a necessary partnership?"],"prefix":"10.1136","volume":"13","author":[{"given":"Gillian","family":"Campbell","sequence":"first","affiliation":[{"name":"Psychiatry, NHS Lanarkshire, Hamilton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Wong","sequence":"additional","affiliation":[{"name":"Psychiatry, NHS Lanarkshire, Hamilton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,12,13]]},"reference":[{"key":"2025082803550549000_13.12.e238377.1","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1001\/jamapsychiatry.2015.1737","article-title":"Premature mortality among adults with schizophrenia in the United States","volume":"72","author":"Olfson","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2025082803550549000_13.12.e238377.2","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/pcn.12420","article-title":"Cancer in patients with schizophrenia: what is the next step?","volume":"70","author":"Chou","year":"2016","journal-title":"Psychiatry Clin Neurosci"},{"key":"2025082803550549000_13.12.e238377.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.psc.2016.01.006"},{"key":"2025082803550549000_13.12.e238377.4","unstructured":"National Institute for Health and Care Excellence (NICE) . Psychosis and schizophrenia in adults: prevention and management (CG178), 2017. Available: https:\/\/www.nice.org.uk\/guidance\/cg178\/resources\/surveillance-report-2017-psychosis-and-schizophrenia-in-adults-prevention-and-management-2014-nice-guideline-cg178-pdf-6041007637189 [Accessed 18 Jun 2020]."},{"key":"2025082803550549000_13.12.e238377.5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-Analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"2025082803550549000_13.12.e238377.6","unstructured":"British National formulary (BNF) clozapine: treatment cessation information. Available: https:\/\/bnf.nice.org.uk\/drug\/clozapine.html#treatmentCessationInformation [Accessed 18 Jun 2020]."},{"key":"2025082803550549000_13.12.e238377.7","unstructured":"British National Formulary (BNF) . Clozapine: cautions. Available: https:\/\/bnf.nice.org.uk\/drug\/clozapine.html#cautions [Accessed 18 Jun 2020]."},{"key":"2025082803550549000_13.12.e238377.8","doi-asserted-by":"publisher","DOI":"10.1177\/2045125314553610"},{"key":"2025082803550549000_13.12.e238377.9","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3209"},{"key":"2025082803550549000_13.12.e238377.10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/ejh.13285","article-title":"Feasibility of myelosuppressive chemotherapy in psychiatric patients on clozapine: a systematic review of the literature","volume":"103","author":"Grainger","year":"2019","journal-title":"Eur J Haematol"},{"key":"2025082803550549000_13.12.e238377.11","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.178.6.576-a"},{"key":"2025082803550549000_13.12.e238377.12","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200305000-00009"},{"key":"2025082803550549000_13.12.e238377.13","doi-asserted-by":"crossref","first-page":"576.e11","DOI":"10.1016\/j.genhosppsych.2013.01.002","article-title":"Add-On filgrastim during clozapine rechallenge unsuccessful in preventing agranulocytosis","volume":"35","author":"Hazewinkel","year":"2013","journal-title":"Gen Hosp Psychiatry"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-238377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:55:17Z","timestamp":1756378517000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-238377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,13]]},"published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1136\/bcr-2020-238377"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-238377","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}